Kolkata: Prices of 42 medicines, including those used for day-to-day consumption, are likely to change following an order by ...
Dapagliflozin plus calorie restriction beneficial for patients with overweight or obesity and type 2 diabetes. (HealthDay News) — For patients with overweight or obesity and type 2 diabetes ...
Diabetes remission was achieved in 44 and 28% of patients in the dapagliflozin and placebo groups, respectively. HealthDay News — For patients with overweight or obesity and type 2 diabetes ...
Diabetes remission was achieved in 44% and 28% of patients in the dapagliflozin and placebo groups, respectively, over 12 months, meeting the predefined primary end point. Yuejun Liu, from Fudan ...
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate ... any anti-diabetic medication other ...
After excluding patients with a range of pre-existing conditions, a history of gastric surgery, and those taking weight loss drugs, participants were randomly assigned to either moderate calorie ...
In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally ...
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much ...
Eligible participants were randomly assigned in a one-to-one ratio to receive 10 mg of dapagliflozin or placebo per day for 12 months, stratified by whether they were treated with metformin at ...
A study published in Diabetes Research and Clinical Practice suggests that dapagliflozin and metformin are well-tolerated and associated with a decreased risk of adverse events. DONATE (NCT03156985) ...